Keeping Track Of Approvals: Two Novel Drugs (Givlaari And Xcopri), A Project Orbis Collaboration (Calquence) And Another Humira Biosimilar

The latest news on US FDA drug approvals.

Keeping Track Feature image

For the third straight year, the US Food and Drug Administration has reached a mark of at least 40 approvals of novel drugs and therapeutic biologics after greenlighting Alnylam Pharmaceuticals Inc.'s Givlaari (givosiran) SK Life Science Inc.'s Xcopri (cenobamate) for the US market.

A major supplemental approval went to AstraZeneca PLC's Calquence (acalabrutinib) for a chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers